

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 June 2006 (08.06.2006)

PCT

(10) International Publication Number
WO 2006/059327 A1

(51) International Patent Classification:
G01N 33/564 (2006.01)

(74) Agent: **REINHOLD COHN AND PARTNERS**; P.O. Box 4060, 61040 Tel Aviv (IL).

(21) International Application Number:
PCT/IL2005/001279

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
30 November 2005 (30.11.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/632,198 2 December 2004 (02.12.2004) US
60/657,718 3 March 2005 (03.03.2005) US

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):
CAN-FITE BIOPHARMA LTD. [IL/IL]; 10 Bareket Street, P.O. Box 7537, 49170 Petach Tikva (IL).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **FISHMAN, Pnina** [IL/IL]; 19 Asher Barash Street, 46365 Herzliya (IL). **BAR-YEHUDA, Sara** [IL/IL]; 21B Arbel Street, 75474 Rishon Le Zion (IL). **MADI, Lea** [IL/IL]; 27 Richard Fienman Street, 75791 Rishon Le Zion (IL).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A BIOLOGICAL MARKER FOR INFLAMMATION



(57) Abstract: Inflammatory state in a subject is assayed by determining the level of expression of A_3 adenosine receptor (A_3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A_3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A_3AR agonist.

WO 2006/059327 A1